WASHINGTON – CDRH Director Jeffrey Shuren encouraged the increased use of real-world evidence (RWE) and put an emphasis on the FDA's total product life cycle (TPLC) reorganization during his presentation last week at the Food and Drug Law Institute's annual conference. At the same time, he provided an overview of CDRH's current activities, including implementation of 21st Century Cures, as well as the center's vision for the future.